Trang 1 từ 87 các kết quả
FIELD OF THE INVENTION
Treatments for estrogen receptor and progesterone receptor negative breast cancer or estrogen receptor, progesterone receptor and c-erbB2 negative (triple negative) breast cancer are provided.
BACKGROUND OF THE INVENTION
Cancer/testis (CT) antigens constitute a unique group of
FIELD OF THE INVENTION
The present invention relates to mouse mammary adenocarcinoma cell lines expressing estrogen and progesterone receptors as a tool to study the effect of hormones, pharmacological compounds, and environmental agents. The present invention also relates to methods in vitro and in
FIELD OF THE INVENTION
The present invention relates to compositions and methods for treating an estrogen-dependent condition. More specifically, the present invention relates to compositions comprising one or more progesterone antagonists for suppressing endometrial proliferation.
BACKGROUND OF THE
FIELD OF THE INVENTION
The present invention relates to compositions and methods for treating an estrogen-dependent condition. More specifically, the present invention relates to compositions comprising one or more progesterone antagonists for suppressing endometrial proliferation.
BACKGROUND OF THE
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to suppressing the growth of cancer and other proliferative diseases by the administering of novel compounds that exhibit progesterone antagonism. The present invention also relates to processes of preparation and
BACKGROUND OF THE INVENTION
Progesterone is a naturally occurring steroid which is the main steroid secreted by women during their reproductive years. This steroid has been studied extensively and has been found to be a major precursor in the biosynthesis of most other steroids, particularly
FIELD OF THE INVENTION
This invention generally relates to expression profiles of genes that are regulated by progesterone receptors, and particularly by progesterone receptor isoforms PR-A and PR-B, and to the use of such genes in methods for identifying progesterone receptor agonist and antagonist
TECHNICAL FIELD
This application relates to regulators of the non-genomic action of progesterone and use of the regulators for treating progesterone related diseases, such as ovarian cancer. The application more specifically relates to pharmaceutical compositions and methods for inducing
FIELD
This application relates to regulators of the non-genomic action of progesterone and use of the regulators for treating progesterone related diseases, such as ovarian cancer. The application more specifically relates to pharmaceutical compositions and methods for inducing progesterone
The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of formula I with progesterone-antagonizing action and methods of production thereof, use thereof for the treatment and/or prevention of diseases and use thereof for the production of medicinal products
This application is a 371 of PCT/JP95/00642 filed Apr. 3, 1995.
TECHNICAL FIELD
The present invention relates to asteroid compound, and more particularly to a novel progesterone compound which has excellent neovascularization inhibitory action, and thus is useful as a remedy for malignant tumors,
FIELD OF THE INVENTION
The present invention relates to the field of antibodies. In particular the present invention discloses an antibody ideal for immunohistochemical staining without difficult target retrieval procedures.
BACKGROUND OF THE INVENTION
A standard technique for medical diagnosis is
FIELD OF THE INVENTION
The present invention relates to methods for diagnosing an increased risk for breast or ovarian cancer by assaying for genetic markers in the human progesterone receptor gene.
BACKGROUND OF THE INVENTION
Breast cancer is the most frequent malignancy in women. A family history
FIELD OF THE INVENTION
The invention provides a method for treatment of primary progesterone receptor-negative (PR-) endometrial cancer comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a progesterone receptor (PR) agonist. The invention further provides a method for
FIELD OF THE INVENTION
The present invention relates to methods for diagnosing an increased risk for breast or ovarian cancer by assaying for genetic markers in the human progesterone receptor gene.
BACKGROUND OF THE INVENTION
Breast cancer is the most frequent malignancy in women. A family history